Literature DB >> 19673049

Tropical medicine rounds: Treatment of Old World cutaneous leishmaniasis with dapsone, itraconazole, cryotherapy, and imiquimod, alone and in combination.

Nawaf Al-Mutairi1, Mazen Alshiltawy, Mohamed El Khalawany, Arun Joshi, Bayoumy Ibrahim Eassa, Yashpal Manchanda, Samir Gomaa, Ibrahim Darwish, Manish Rijhwani.   

Abstract

BACKGROUND: Cutaneous leishmaniasis (CL) is a major public health problem. The currently available therapies are expensive, not freely available, toxic, and not always curative. A simple, effective, noninvasive therapeutic approach is required for the treatment of CL. AIMS: To determine the clinical patterns of CL and to report our experience in the management of CL.
METHODS: One hundred and ten patients with CL seen between January 2005 and December 2007 were included in this study. The diagnosis was based on clinical features, parasitologic diagnosis, histopathology, and culture. Each patient was treated according to disease severity with either topical (cryotherapy or imiquimod) or systemic (itraconazole or dapsone) monotherapy, or a combination of these modalities.
RESULTS: CL was more common in adult expatriate men, with the upper limbs as the most commonly affected site. Noduloulcerative CL was the most common presentation (84.6%). Atypical CL was found in 18 patients. Skin biopsy was the most common diagnostic technique (66.6%). Monotherapy showed an overall success rate of 56.41%, whereas combination therapy was successful in 69.56% of cases. Cryotherapy alone was successful in 68.18% of cases. Imiquimod alone was ineffective.
CONCLUSION: A stepwise approach represents a rational and practical way of confirming CL. A combination of itraconazole/dapsone and topically applied imiquimod is safe, simple, and effective for the treatment of CL. More studies are needed to establish the role of such an approach. Cryotherapy is also safe, simple and effective for the treatment of CL.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19673049     DOI: 10.1111/j.1365-4632.2008.04010.x

Source DB:  PubMed          Journal:  Int J Dermatol        ISSN: 0011-9059            Impact factor:   2.736


  6 in total

1.  Molecular factors governing inhibition of arylimidamides against Leishmania: conservative computational modeling to improve chemotherapies.

Authors:  Catharine J Collar; Xiaohua Zhu; Karl Werbovetz; David W Boykin; W David Wilson
Journal:  Bioorg Med Chem       Date:  2011-06-16       Impact factor: 3.641

2.  Topical resiquimod protects against visceral infection with Leishmania infantum chagasi in mice.

Authors:  Noah Craft; Ron Birnbaum; Natalie Quanquin; Marie Crisel B Erfe; Cara Quant; Jacquelyn Haskell; Kevin W Bruhn
Journal:  Clin Vaccine Immunol       Date:  2014-07-16

3.  Diffuse cutaneous leishmaniasis - A rare cutaneous presentation in an HIV-positive patient.

Authors:  Hemang M Purohit; Asha N Shah; Bipin K Amin; Manoj R Shevkani
Journal:  Indian J Sex Transm Dis AIDS       Date:  2012-01

4.  Comparison of Intralesional Meglumine Antimonite along with oral Itraconazole to Intralesional Meglumine Antimonite in the treatment of Cutaneous Leishmaniasis.

Authors:  Uzma Bashir; Moizza Tahir; Muhammad Irfan Anwar; Faisal Manzoor
Journal:  Pak J Med Sci       Date:  2019 Nov-Dec       Impact factor: 1.088

5.  Efficacy of cryotherapy for the treatment of cutaneous leishmaniasis: meta-analyses of clinical trials.

Authors:  Liliana López-Carvajal; Jaiberth Antonio Cardona-Arias; María Isabel Zapata-Cardona; Vanesa Sánchez-Giraldo; Iván Darío Vélez
Journal:  BMC Infect Dis       Date:  2016-07-26       Impact factor: 3.090

Review 6.  Efficacy of azole therapy for tegumentary leishmaniasis: A systematic review and meta-analysis.

Authors:  Endi Lanza Galvão; Ana Rabello; Gláucia Fernandes Cota
Journal:  PLoS One       Date:  2017-10-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.